AllergoOncology: Danger signals in allergology and oncology: A European Academy of Allergy and Clinical Immunology (EAACI) Position Paper - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Allergy Année : 2022

AllergoOncology: Danger signals in allergology and oncology: A European Academy of Allergy and Clinical Immunology (EAACI) Position Paper

Christoph Bergmann
Aurélie Poli
Ioana Agache
Rodolfo Bianchini
Heather J Bax
Mariana Castells
Silvia Crescioli
Denisa Ferastraoaru
Edda Fiebiger
Hannah J Gould
Karin Hartmann
Elena Izquierdo
Galateja Jordakieva
Debra H Josephs
Marek Jutel
Francesca Levi‐schaffer
Leticia de las Vecillas
Michael T Lotze
Gabriel Osborn
Mariona Pascal
Frank Redegeld
David Rosenstreich
Franziska Roth‐walter
Carsten Schmidt‐weber
Mohamed Shamji
Esther H Steveling
Michelle C Turner
Eva Untersmayr
Erika Jensen‐jarolim
Sophia N Karagiannis

Résumé

Abstract The immune system interacts with many nominal ‘danger’ signals, endogenous danger‐associated (DAMP), exogenous pathogen (PAMP) and allergen (AAMP)‐associated molecular patterns. The immune context under which these are received can promote or prevent immune activating or inflammatory mechanisms and may orchestrate diverse immune responses in allergy and cancer. Each can act either by favouring a respective pathology or by supporting the immune response to confer protective effects, depending on acuity or chronicity. In this Position Paper under the collective term danger signals or DAMPs, PAMPs and AAMPs, we consider their diverse roles in allergy and cancer and the connection between these in AllergoOncology. We focus on their interactions with different immune cells of the innate and adaptive immune system and how these promote immune responses with juxtaposing clinical outcomes in allergy and cancer. While danger signals present potential targets to overcome inflammatory responses in allergy, these may be reconsidered in relation to a history of allergy, chronic inflammation and autoimmunity linked to the risk of developing cancer, and with regard to clinical responses to anti‐cancer immune and targeted therapies. Cross‐disciplinary insights in AllergoOncology derived from dissecting clinical phenotypes of common danger signal pathways may improve allergy and cancer clinical outcomes.
Fichier principal
Vignette du fichier
ALL-77-2594.pdf (9.97 Mo) Télécharger le fichier
Origine Publication financée par une institution
Licence
Domaine public

Dates et versions

hal-04357830 , version 1 (21-12-2023)

Licence

Domaine public

Identifiants

Citer

Christoph Bergmann, Aurélie Poli, Ioana Agache, Rodolfo Bianchini, Heather J Bax, et al.. AllergoOncology: Danger signals in allergology and oncology: A European Academy of Allergy and Clinical Immunology (EAACI) Position Paper. Allergy, 2022, 77 (9), pp.2594-2617. ⟨10.1111/all.15255⟩. ⟨hal-04357830⟩
4 Consultations
5 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More